Principles of Effective Antibiotic Therapy
Lecture Handout — Slides 1–62
1 Introduction: Antibiotics — The Medical Miracle
1.1 Medicine in the Pre-Antibiotic Era
Prior to the availability of antibiotics, medicine was largely a process of prognostication rather than intervention. Physicians could predict the course of infectious diseases but had little ability to alter outcomes. Treatments were rudimentary and often ineffective — prescriptions frequently consisted of alcohol-based preparations such as spiritus frumenti (whiskey) or high-proof herbal tonics like Jamaican ginger (90% alcohol).
1.2 Dawn of Antibiotic Discovery
Although evidence suggests antibiotic-like substances were used by ancient civilizations — Egyptians produced tetracycline-containing beer using Streptomyces-contaminated grain, and the Greeks and Chinese employed various antimicrobial remedies — the first truly effective systemic antibiotics emerged in the early 20th century.
| Paul Ehrlich (1909) Salvarsan — first treatment for syphilis; highly toxic, required skilled administration | Alexander Fleming (1929) Penicillin discovery; purified and tested by Florey, Chain & Heatley (1940) | Gerhard Domagk (1931) Sulfonamides — discovered through textile dye research; treated his own daughter’s severe cellulitis before human trials |
|---|---|---|
 |
 |
 |
1.3 Mortality Reduction with Antibiotic Therapy
The impact of antibiotics on mortality from common infectious diseases is unparalleled by any other class of therapeutic drugs — far exceeding the impact of treatments for myocardial infarction, stroke, or cancer.
| Disease | Pre-antibiotic era | Antibiotic era | Mortality reduction |
|---|---|---|---|
| Community-acquired pneumonia | ~35% | ~10% | −25% |
| Nosocomial pneumonia | ~60% | ~30% | −30% |
| Bacterial endocarditis | ~100% | ~25% | −75% |
| Gram-negative bacteremia | ~70% | ~10% | −60% |
| Bacterial meningitis | >80% | <20% | −60% |
| Cellulitis | ~11% | <0.5% | −10.5% |
1.4 Antibiotics: Essential for Modern Medicine
Beyond treating infections directly, antibiotics enable virtually every aspect of modern interventional medicine:
- Complex surgery — deeply invasive and prolonged surgical procedures
- Cancer chemotherapy — aggressive cytotoxic regimens that suppress immunity
- Critical care — maintenance of patients with central venous catheters, mechanical ventilation
- Neonatal medicine — care for premature infants and mothers with post-partum sepsis
- Transplantation — solid organ and stem cell transplantation
Antibiotics created a revolution in the practice of medicine, transforming a primarily diagnostic-focused field into a therapeutic, interventional profession. (Spellberg, 2025)
Without effective antibiotics, medicine would regress approximately 100 years — losing the ability to safely perform these high risk procedures.
2 The Antimicrobial Resistance Crisis
2.1 Global Impact of Resistance
Antimicrobial resistance (AMR) represents one of the most significant threats to global public health. Current global statistics reveal the scale of the problem:
- 21.6 million deaths due to sepsis annually
- 7.75 million deaths due to bacterial infections
- 4.7 million deaths associated with resistance (requiring less effective or more toxic antibiotics)
- >1 million deaths directly attributable to resistance
In Italy specifically, approximately 8,000 deaths per year are attributable to antibiotic-resistant infections — a figure that receives remarkably little public attention relative to its magnitude.
2.2 WHO Priority Pathogen List
The World Health Organization has classified resistant pathogens into three priority tiers to guide research and development of new antibiotics:
2.2.1 Critical Priority (all Gram-negatives)
These are pathogens typically acquired by hospitalized, immunocompromised, or critically ill patients, often emerging after multiple courses of antibiotic therapy:
- Acinetobacter baumannii — often begins as colonization in ventilated or burn patients; progresses to pneumonia, bloodstream infection, and sepsis; frequently multi-drug resistant (MDR) and sometimes pan-drug resistant (PDR)
- Pseudomonas aeruginosa — associated with immunocompromised and critically ill patients; commonly MDR
- Carbapenem-resistant Enterobacterales — E. coli, Klebsiella pneumoniae, Enterobacter spp. — the most common causes of urinary tract infections and bloodstream infections, now increasingly resistant to carbapenems (previously considered last-line agents)
2.3 Resistance Rates in Italy and Europe
2.3.1 Methicillin-resistant Staphylococcus aureus (MRSA)
In Italy, 25–50% of S. aureus isolates are methicillin-resistant, necessitating the use of intravenous antibiotics such as vancomycin or daptomycin that are more toxic, more expensive, and require prolonged hospitalization compared to oral alternatives available for methicillin-susceptible strains.
2.3.2 Carbapenem-resistant Enterobacterales (CRE)
Up to 25% of Klebsiella pneumoniae hospital isolates in Italy are resistant to carbapenems. This has transformed the mortality of common Gram-negative bloodstream infections from approximately 8–10% to 40–50%, because physicians must resort to less effective combination regimens.
2.3.3 Multi-drug Resistant Acinetobacter baumannii
Northern European countries have lower resistance rates due to: (1) lower per-capita antibiotic use, (2) stricter infection control practices and culture, (3) modern hospital infrastructure with fewer multipatient rooms. However, resistance travels with people — international travel and migration disseminate resistant organisms globally.
For example: Antibiotic consumption (defined daily doses or DDD per 1,000 inhabitants per day):
Netherlands, Sweden: ~8–12
Germany, Denmark: ~10–14
Italy, Spain: ~18–25
Greece: ~30–35
2.4 The Antibiotic Discovery Pipeline Is Slowing
Antibiotic development is declining because:
- High cost and risk — developing a new antibiotic costs approximately $1 billion
- Poor return on investment — hospitals appropriately restrict new antibiotics to preserve them, reducing sales
- Competition with profitable drug classes — antibiotics cannot compete commercially with GLP-1 inhibitors, statins, or other drugs taken daily for life
- No novel mechanisms — recent approvals are iterations of existing classes, not truly new drug classes
New funding models are needed. Italy has passed measures supporting a “Netflix model” — paying a subscription fee to ensure antibiotics are available when needed, regardless of usage volume. Antibiotics can also be thought of like fire extinguishers: you hope you never need them, but someone must pay to keep them functional (see this blog by Dr. John Rex for more information.
2.5 Antibiotics Are a Societal Trust
Antibiotic overprescription is a tragedy of the commons: an individual undertakes an action perceived to be in their own self-interest that causes harm to society at large.
- >1/3 of community antibiotic prescriptions are inappropriate
- Up to 50% of hospital antibiotic prescriptions may be inappropriate
- Each inappropriate prescription individually causes minimal harm, but collectively the effect is catastrophic
One of the most important functions of the physician is to serve as an expert steward — both using antibiotics effectively and protecting their efficacy for future patients.
3 The Ten Principles of Effective Antibiotic Therapy
- Develop an accurate differential diagnosis
- Only use antibiotics when they alter the clinical course
- Empirically target microbes in the differential diagnosis
- Use a lower threshold for empirical therapy in critically ill patients
- Host factors affect the spectrum of empirical therapy
- Use PK/PD principles to optimize treatment selection and dosing
- De-escalate therapy based on microbiology results and clinical response
- If therapy is not working, consider source control or alternative diagnosis before broadening
- Distinguish new infection from failure of initial therapy
- Duration of therapy should be as short as possible based on evidence
This handout covers Principles 1–6 in detail, as presented in the lecture.
4 Principle 1: Develop an Accurate Differential Diagnosis
4.1 The Medical History Is 80% of Diagnosis
In infectious diseases, the patient’s medical history — not imaging, biomarkers, or even microbiological tests — is the single most important diagnostic tool. This may seem counterintuitive, but there are important reasons:
- Microbiological tests, while confirmatory, are not perfectly sensitive or specific
- Ordering tests in patients with low pre-test probability leads to false positives that can trigger unnecessary invasive procedures or toxic treatments
- Broad-panel testing without clinical context produces incidental findings that mislead clinicians
4.1.1 Key Elements of the Infectious Disease History
- Current symptoms — assessed using the 8 cardinal descriptors: Timing, Location, Character, Aggravating factors, Alleviating factors, Associated symptoms, Severity, Setting
- Fever — height, duration, pattern (continuous, intermittent, relapsing)
- Risk factors — indwelling devices (urinary catheters, vascular catheters, prosthetic joints, cardiac devices), recent procedures, immunosuppression, diabetes, injection drug use, previous infections
- Travel and exposure history — countries, regions (urban vs. rural), dates, animal or insect exposure, contact with ill individuals, consumption of potentially contaminated food/water
- Sexual history and STI risk
- Vaccination history
- Past medical, surgical, medication history, and allergies
- Recent antibiotic use
- Social history — long-term care facility residence, occupation, hobbies, substance use, unusual exposures
4.2 Case Example: The Importance of History
4.2.1 Clinical Presentation
A 34-year-old farmer from Sicily presents with worsening back pain after sitting for more than a couple of hours. MRI reveals evidence of inflammation and septic discitis at the L4 vertebral body, suggesting spondylitis.
4.2.1.1 Standard Spondylitis Etiologies
The most common causes of vertebral osteomyelitis/spondylitis are:
- >50%: Staphylococcus aureus, S. epidermidis
- ~25%: Streptococcus spp., Enterococcus spp., Pseudomonas aeruginosa, Enterobacterales, anaerobes, Mycobacterium tuberculosis (Pott’s disease)
These are typically hematogenously spread infections, classically occurring in hospitalized patients after central venous catheter use or staphylococcal bacteremia.
4.2.2 The History Changes Everything
Pertinent history reveals:
- Patient is a sheep and cattle farmer producing milk and cheese (Pecorino salato and Ricotta)
- Pain began after a “bad case of flu” with fever, achy joints, and headache
- Father (also works on the farm) has worsening hip pain — being evaluated for hip replacement
- From an endemic area for zoonotic infections in southern Italy
4.2.3 Diagnosis: Brucellosis Spondylitis
The standard diagnostic workup and treatment for staphylococcal spondylitis would completely miss this diagnosis:
| Aspect | Standard spondylitis | Brucellosis spondylitis |
|---|---|---|
| Blood cultures | Standard incubation | Prolonged incubation required; bone marrow biopsy may be needed |
| Specific tests | Not required | Brucella PCR, combination serologic studies |
| Treatment | Vancomycin or anti-staphylococcal agents | Gentamicin + Doxycycline + Rifampin — completely unconventional |
Key teaching point: The history informed everything — from diagnostic test selection to treatment. Starting empirical vancomycin (the standard approach) would have been completely ineffective against Brucella.
4.3 Antibiotics Are Usually Started Empirically
In practice, antibiotic therapy is initiated before microbiological results are available, because the most critical window for treatment is the first 24–48 hours when bacterial inoculum is highest and patients are sickest.
4.3.1 Timeline from Suspicion to Definitive Therapy
| Time | Step | Action |
|---|---|---|
| 0 hours | Suspect infection | Clinical assessment |
| ~1 hour | Culture suspected sites | Begin empiric therapy for likely pathogens |
| ~24 hours | Gram stain results | Preliminary guidance for therapy adjustment |
| 36–48 hours | Pathogen identification | Consider narrowing therapy |
| 72–96 hours | Susceptibility results | Switch to definitive therapy |
4.3.2 The Problem of Empirical Overuse
Because empirical therapy is started before diagnosis, this inherently leads to overuse:
- >90% of upper respiratory tract infections are viral and should not be treated with antibiotics
- Clinicians frequently overestimate the risk of bacterial infection
- Clinicians frequently underestimate the risks of antibiotic therapy
4.4 Risks of Antibiotic Therapy Are Underappreciated
- 1 in 5 patients given an antibiotic prescription develops an adverse event or superinfection (resistant pathogens or Clostridioides difficile)
- Each additional 10 days of antibiotic therapy confers a 3% increased risk of an adverse drug effect
This results from a combination of (1) fear from diagnostic uncertainty, and (2) lack of appreciation for how dangerous antibiotics can be (Tamma et al., 2017).
4.4.1 Most Common Antibiotic-Associated Adverse Events in Hospitalized Patients
4.5 Positive Cultures Are Not Always Proof of Infection
A positive culture in the absence of signs and symptoms of infection should not reflexively trigger antibiotic therapy. Without clinical symptoms, positive cultures often represent colonization or contamination.
Common offenders include:
| Sample type | Problem |
|---|---|
| Superficial wound swabs | Sample skin flora, not the pathogen causing deep infection; deep tissue biopsy at infection margins is required |
| Urine cultures | Catheterized patients always have positive cultures; asymptomatic bacteriuria should not be treated |
| Bronchoalveolar lavage | Can become contaminated with oral flora during bronchoscope withdrawal |
| Respiratory samples | Low positive predictive value without compatible symptoms |
| Stool cultures | Unreliable without active diarrhea at time of collection |
4.5.1 Diagnostic Stewardship Works
Simple interventions can dramatically reduce inappropriate testing. A study by Luu et al. placed reminders at nursing stations with key messages:
Stop sending urine cultures for everything nosocomial. Cystitis doesn’t cause fevers. Urine from the catheter is not sterile. A positive urine culture does not equal infection.
5 Principle 2: Only Use Antibiotics When They Alter the Clinical Course
5.1 Antibiotics Are Not the Only Answer
The administration of antibiotics should not be a reflexive response to infection. It should be incorporated into an overall, rational therapeutic plan. Key considerations:
- Patients without bacterial infections cannot have their clinical course improved by antibiotics
- Some infections require non-antibiotic interventions first before antibiotics will be effective
5.1.1 Classic Example: Osteomyelitis with Exposed Bone
If the bone remains exposed, starting antibiotics will:
- Fail to clear the infection
- Select for increasingly resistant organisms
- Leave the patient with an untreatable MDR bone infection
The proper approach: achieve surgical closure/source control first, then initiate appropriate antibiotic therapy.
5.2 Ethical Dilemmas
Two common ethical scenarios:
| End-of-life care | Non-adherent HIV therapy |
|---|---|
 |
 |
| Should infections be treated aggressively in terminally ill patients? Generally yes for comfort, but the extent of treatment for MDR infections in terminal stages remains debated. | If a patient is non-adherent, antibiotic/antiviral therapy risks transforming their infection into a resistant, untreatable, and potentially transmissible disease. |
6 Principle 3: Empirically Target Microbes in the Differential Diagnosis
6.1 Know the Spectrum of Activity
To select appropriate empiric therapy, clinicians must know which antibiotics cover which pathogens. The Sanford Guide (web.sanfordguide.com) provides comprehensive antimicrobial spectra tables using a grading system:
- ++ (double plus) — good activity with clinical evidence from trials
- + (green) — good in vitro activity expected to be effective, but possibly lacking clinical trial data for the specific indication
- ± (yellow/borderline) — resistance or pharmacokinetic concerns; unreliable
- 0 (red) — ineffective; do not use
6.1.1 The Impact of Resistance on Treatment Options
Consider the dramatic narrowing of treatment options with increasing resistance in E. coli:
| Resistance phenotype | Available options | Key drugs remaining |
|---|---|---|
| Susceptible E. coli | Many options across multiple classes | Amoxicillin-clavulanate, piperacillin-tazobactam, cephalosporins, carbapenems, fluoroquinolones |
| ESBL-producing E. coli (25–30% of hospital isolates) | Dramatically reduced | Primarily carbapenems |
| KPC/MBL carbapenemase-producing E. coli | Only 1–2 options, none with strong clinical evidence | Newer agents (ceftazidime-avibactam, cefiderocol) with limited clinical data |
6.2 Community-Acquired vs. Nosocomial Infections
The single most important question in selecting empiric therapy is: where was this infection acquired?
| Feature | Community infections | Nosocomial infections |
|---|---|---|
| MDR Gram-negatives | Infrequent | Common |
| MRSA risk | Low (unless specific risk factors) | High, especially with recent antibiotic use |
| Typical pathogens | S. pneumoniae, H. influenzae, M. catarrhalis, atypical pathogens | Pseudomonas, MRSA, non-fermenting Gram-negatives, Enterobacterales |
| Empiric approach | Narrow-spectrum oral therapy often sufficient | IV broad-spectrum therapy, consider ESBL/CRE coverage |
| Last-line agents | Reserve (e.g., fluoroquinolones) | May need as first-line |
Community-acquired infections may be caused by Pseudomonas in patients with cystic fibrosis, bronchiectasis, chronic dialysis, indwelling catheters, or recent surgery.
7 Principle 4: Lower Threshold for Empirical Therapy in Critically Ill Patients
7.1 Antibiotic Timing Is Critical in Septic Shock
In critically ill patients with sepsis, there is no time for prolonged diagnostic deliberation. Observational evidence demonstrates that each hour of delay in administering appropriate antimicrobial therapy increases the risk of death.
7.1.1 Key Clinical Actions in Septic Shock
- Obtain blood cultures before starting antibiotics — this is your best chance for a microbiological diagnosis (sensitivity drops after antibiotics are started)
- Start broad-spectrum empirical therapy immediately — a carbapenem or other broad-spectrum regimen
- Ensure subsequent doses are administered on time — the first AND second doses are critical
- De-escalate once culture results are available
In septic patients, you may need to start broader empirical therapy than you would in a stable patient. The risk of undertreating a critically ill patient with an inadequate antibiotic far outweighs the collateral damage of temporary broad-spectrum therapy.
8 Principle 5: Host Factors Affect the Spectrum of Empirical Therapy
8.1 Immunocompromise Changes the Differential Diagnosis
The “flavor” of immunosuppression determines the types of pathogens that must be considered:
Key question: Does this patient have impaired cell-mediated immunity? If so:
- Acute presentation → viral infections, common bacteria, intracellular bacteria (Legionella, Listeria, Salmonella Typhi, Nocardia)
- Delayed/subacute presentation → fungal infections (Candida, Aspergillus), parasites
- Standard β-lactams will not cover intracellular pathogens
8.1.1 Common Immunocompromising Conditions
- Chronic diseases (type 1 diabetes, COPD)
- Autoimmune diseases (lupus, rheumatoid arthritis)
- Primary immunodeficiencies
- Cancer and/or chemotherapy
- HIV
- Solid organ or bone marrow transplant
- Advanced age
- Malnutrition
- Chronic corticosteroid use or other immunosuppressive medications
- Chronic infections
- Smoking (impaired ciliary response)
8.2 Glucocorticoids: The “Credit Cards” of Immunosuppressive Therapy
Corticosteroids provide immediate anti-inflammatory benefit (like a credit card) but accrue a compounding “debt” of immunosuppression — the bill comes due as opportunistic infections.
9 Principle 6: Use PK/PD Principles to Optimize Treatment Selection and Dosing
9.1 It’s Not Enough to Pick the Right Drug
Selecting an antibiotic with appropriate pharmacodynamic (PD) activity — the right spectrum — is only half the equation. You must also consider the pharmacokinetic (PK) properties: does the drug reach the site of infection at adequate concentrations?
Pharmacodynamics (spectrum, MIC, potency) — you cannot control whether the pathogen is intrinsically or acquired resistant.
Pharmacokinetics (absorption, distribution, metabolism, elimination) — you can control the dose, route, and administration schedule to maximize drug exposure at the infection site.
9.2 Key Pharmacokinetic Variables
9.2.1 The Concentration-Time Curve
9.2.2 Volume of Distribution (Vd)
The Vd is a theoretical volume that relates the total amount of drug in the body to the plasma concentration. It is estimated, not directly measured, and reported in liters (L) or liters per kilogram (L/kg).
- Average plasma volume in adults ≈ 3 L
- Plasma + interstitial fluid ≈ 13–14 L
- Total body water ≈ 20 L (plasma + extracellular water)
9.2.2.1 Clinical Significance of Vd
Interpretation:
- Low Vd (≤20 L): Drug concentrates in the bloodstream → better for bloodstream infections (e.g., β-lactams, aminoglycosides)
- High Vd (>46 L): Drug is sequestered in tissues (fat, skin, nails) → serum concentrations will be low → poor choice for bloodstream infections, but may be useful for tissue infections
- Low Vd drugs (β-lactams, aminoglycosides, vancomycin) → preferred for bloodstream infections, endocarditis
- High Vd drugs (macrolides, doxycycline, tigecycline, rifampin) → useful for pneumonia, deep tissue infections but NOT for high-grade bacteremia
Historical failures: early endocarditis studies showed poor outcomes with tetracyclines and macrolides (high Vd, low blood levels) compared to penicillins (low Vd, high blood levels) — this led to the erroneous conclusion that “bactericidal” drugs are inherently superior to “bacteriostatic” drugs, when the real issue was pharmacokinetics.
9.2.2.2 Vd Changes in Disease States
Vd is not static — it can be altered by:
- Body mass, age, sex, pregnancy
- Kidney disease, liver disease
- Drug interactions (displacement of protein binding)
- Critical illness and sepsis
9.2.2.3 Vd Changes in Critical Illness — A Major Clinical Problem
Practical consequence: In septic patients, the “beaker” (Vd) gets much bigger. A standard dose that would produce adequate concentrations in a non-septic patient may result in subtherapeutic levels, contributing to treatment failure and resistance emergence.
9.2.3 The DALI Study: ICU Underdosing Is the Rule, Not the Exception
A landmark multicenter study across 60–65 ICUs in Europe and Australia sampled β-lactam concentrations in critically ill patients at leading academic medical centers:
- >1/3 of patients did not achieve even the minimum PK/PD target for efficacy
- >2/3 of patients did not achieve the more aggressive target needed to prevent resistance emergence
We routinely underdose critically ill patients with sepsis — the exact population where our biggest resistance problems occur. This is because antibiotic doses were established in studies of patients with urinary tract infections or mild intra-abdominal infections, not in septic ICU patients.
9.3 Drug Penetration and Site-Specific Considerations
9.3.1 Ventilator-Associated Pneumonia
The lungs represent one of the most challenging sites for antibiotic penetration, which is why ventilator-associated pneumonia is one of the most common settings for resistance emergence.
9.3.2 Anatomically Privileged Sites
Certain body compartments have barriers that restrict antibiotic penetration:
9.3.3 Using Site-Specific Pharmacokinetics to Advantage
Not all pharmacokinetic barriers work against us. Some sites concentrate antibiotics:
9.3.3.1 Urinary Tract: A Major Advantage
Many antibiotics are excreted through the kidneys and achieve urinary concentrations vastly exceeding serum levels. This means some antibiotics may be effective for UTIs even when the laboratory reports “resistant,” because the urinary concentrations surpass the MIC.
| Antibiotic class | Serum concentration | Urinary concentration |
|---|---|---|
| Fluoroquinolones | 1.6–2.9 µg/mL | ~350 µg/mL |
| β-lactams | 3–6 µg/mL | 1,000–2,250 µg/mL |
| Aminoglycosides | 4–8 (or 17–25) µg/mL | Hundreds to thousands µg/mL |
9.4 Clearance: The Second Key PK Variable
9.4.1 Vd vs. Clearance: Critical Distinctions
| Parameter | Determines | Clinical use |
|---|---|---|
| Volume of distribution (Vd) | How much drug distributes into tissues | Loading dose — fill the “tank” |
| Clearance (CL) | How fast the body eliminates drug | Maintenance dose — how often and how much to give |
- Vd and CL are both physiologically based but do not directly interact with each other
- A change in Vd does not change clearance, and vice versa
- CL is NOT used to determine the initial (loading) dose — only Vd matters for that
9.4.2 Renal Dose Adjustment
Most antibiotics are eliminated via the kidneys, and maintenance doses must be adjusted for renal function.
9.4.3 Estimating Renal Function
The Cockcroft-Gault formula is commonly used:
\[ \text{CrCl (mL/min)} = \frac{(140 - \text{age}) \times \text{weight (kg)}}{72 \times \text{SCr (mg/dL)}} \times 0.85 \text{ (if female)} \]
Important limitations:
- Developed primarily in Caucasian males with chronic renal disease
- Does not account for older age, comorbidities, or drug interactions with renal tubular secretion
- Not validated in patients with acute kidney injury or sepsis
9.4.4 Critical Problem: Premature Renal Dose Reduction
Reducing the FIRST dose based on renal function — the first dose should be based on Vd (to fill the “tank”), NOT on clearance. Never reduce the loading dose.
Reducing doses in patients with REVERSIBLE renal dysfunction — up to 50% of patients with acute infection have acute (not chronic) renal impairment that frequently resolves within 48 hours with fluid resuscitation. Premature dose reduction leads to subtherapeutic antibiotic concentrations during the most critical treatment window.
Antibiotic renal dose adjustments in drug labels are based on patients with chronic kidney disease. However, in infectious disease:
- Renal dysfunction is frequently acute, not chronic
- Serum creatinine changes are delayed — creatinine decreases lag behind actual improvement in kidney function
- Using serum creatinine to dose antibiotics in acute illness is like “driving by only looking in the rearview mirror” (Crass et al., 2019)
Practical guidance: If a patient presents severely dehydrated and hypotensive with an elevated creatinine, and you believe this is acute and reversible with fluids, do not reduce antibiotic doses in the first 48 hours (especially for safe antibiotics like β-lactams). The risk of undertreating the infection during the critical early period outweighs the risk of a brief period of higher drug levels.
The first dose of an antibiotic in a septic patient is determined by Vd (to fill the expanded volume). Clearance determines subsequent maintenance doses. Even in patients with renal dysfunction — give the full first dose, then adjust maintenance based on kidney function trends.
10 Summary of Key Concepts (Slides 1–62)
This section of the lecture establishes six foundational principles for antibiotic therapy:
The medical history drives everything — from diagnostic test selection to empiric therapy choices. The brucellosis case illustrates how history completely redirects the approach.
Antibiotics are powerful but not benign — 1 in 5 patients experience adverse events; they should only be used when they can alter clinical outcomes. Source control must precede or accompany antibiotic therapy.
Know your bugs and drugs — spectrum of activity varies dramatically based on resistance phenotype. Community vs. nosocomial acquisition fundamentally changes pathogen probability.
Time kills in sepsis — every hour of delayed appropriate therapy increases mortality. Start broad, obtain cultures first, then de-escalate.
Immunosuppression broadens the differential — particularly cell-mediated immunity defects. Corticosteroids are a “hidden” source of immunosuppression that can lead to unexpected opportunistic infections.
Pharmacokinetics matter as much as spectrum — Vd determines where the drug goes (loading dose), clearance determines how long it stays (maintenance dose). ICU underdosing is endemic and contributes to resistance. Match the drug’s pharmacokinetic profile to the site of infection.